A carregar...
Open-Label Trial of Ranolazine for the Treatment of Paramyotonia Congenita
INTRODUCTION: Paramyotonia congenita (PMC) is a non-dystrophic myotonic disorder that is believed to be caused by a defect in Na(v)1.4 sodium channel inactivation. Ranolazine, which acts by enhancing slow inactivation of sodium channels, has been proposed as a therapeutic option, but in vivo studies...
Na minha lista:
| Publicado no: | Muscle Nerve |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6340713/ https://ncbi.nlm.nih.gov/pubmed/30390395 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/mus.26372 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|